FRC
FRC Logo
Community
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years
Rate us on TrustpilotLeave a review

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us
  • Leave a Review

Resources

  • Videos
  • Research Reports
  • Community
  • FAQ
  • How to use the site

Browse

  • Stock Directory
  • Stock Screener
  • Market Intel Weekly
  • Report Archive

Trackers

  • Congress Trading
  • Senate Trading
  • Congress Net Worth
  • Markets

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Strategies
Intel
Analysis
Community
Company ProfileTelix Pharmaceuticals Limited
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
TLX.AX
Telix Pharmaceuticals Limited Stock AnalysisComprehensive stock analysis for Telix Pharmaceuticals Limited (TLX.AX) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisTLX.AX
TLX.AX
Telix Pharmaceuticals Limited
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
TLX.AX
  1. Home
  2. Stocks
  3. Telix Pharmaceuticals Limited

Telix Pharmaceuticals Limited

🇦🇺TLX.AX•ASX

Telix Pharmaceuticals Limited

🇦🇺TLX.AX•ASX
P/E ratio
89.35

Your view on TLX.AX

P/E
89.35
Your view
Company Overview

Overview

What the company does, where it operates, and who runs it.

About Telix Pharmaceuticals Limited

Industry
Biotechnology
Sector
Healthcare
CEO
Christian Behrenbruch
Headquarters
55 Flemington Road, North Melbourne, VIC, AU
Industry
Biotechnology
Sector
Healthcare
CEO
Christian Behrenbruch
Headquarters
55 Flemington Road, North Melbourne, VIC, AU
Description

Telix Pharmaceuticals Limited is an Australian-based radiopharmaceutical company dedicated to pioneering molecularly targeted radiation (MTR) products.

These innovations are developed for the diagnosis and treatment of various cancers and rare conditions, with its global presence encompassing Australia, Belgium, Japan, Switzerland, and the United States. The company's robust pipeline includes several leading candidates.

TLX591-CDx is engineered for the diagnosis and treatment of metastatic castrate-resistant prostate cancer, while TLX66-CDx is designed for bone marrow conditioning and rare diseases.

In advanced clinical development, TLX250-CDx is in Phase III trials for renal (kidney) cancer diagnosis and treatment, alongside TLX250 in Phase II for the same indication. TLX591 is also undergoing Phase III trials for metastatic castrate-resistant prostate cancer.

For glioblastoma (brain cancer), TLX101 and TLX101-CDx are currently in Phase I/II studies, and TLX66 is in Phase I/IIa trials for bone marrow conditioning and rare diseases. Beyond these flagship programs, Telix is actively developing TLX592, a targeted alpha therapy candidate for prostate cancer.

Its portfolio also features TLX591-Sx, a versatile PET tracer capable of both PET and fluorescent (optical) imaging, and TLX599-CDx, an investigational prostate cancer imaging agent utilizing single-photon emission computed tomography (SPECT). Strategic collaborations are integral to Telix's operations.

This includes a significant license and commercial partnership with China Grand Pharmaceutical and Healthcare Holdings Limited for MTR product development, a scientific and clinical research alliance with Mauna Kea Technologies, and a strategic collaboration agreement with Lightpoint Medical, Ltd. Founded in 2015, the company's headquarters are located in North Melbourne, Australia.

Financial Data

Stock Data

Price chart, volume, and trading data.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

About this section

Valuation, profitability, liquidity and leverage ratios for Telix Pharmaceuticals Limited. Starting points for Telix Pharmaceuticals Limited: P/E 89.4, EPS AUD 0.10, beta 0.63 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

About this section

Dividend history, yield and payout sustainability for Telix Pharmaceuticals Limited. Telix Pharmaceuticals Limited does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

About this section

Reported vs. expected earnings history for Telix Pharmaceuticals Limited. Trailing twelve-month EPS for Telix Pharmaceuticals Limited stands at AUD 0.10. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.

Wall Street Analyst Estimates

Analysts' price targets, ratings, and revenue and EPS estimates.

Wall Street analysts· not FRC research
Nov 21, 2026
More →

Earnings per share estimates

Per shareThis quarterDec 2026Next quarterJun 2027This yearYear to Dec 2026Next yearYear to Dec 2027
Average estimate−$0.12−$0.07$0.12$0.07
Lowest estimate−$0.14−$0.08−$0.07−$0.49
Highest estimate−$0.09−$0.06$0.37$0.57
Number of analysts11117
A year ago$0.181−$0.011−$0.021—
Growth vs a year ago————

1The year-ago figure includes one-time items, so growth is not shown.

Revenue estimates

TotalThis quarterDec 2026Next quarterJun 2027This yearYear to Dec 2026Next yearYear to Dec 2027
Average estimate$29.52M$127.62M$1.46B$1.88B
Lowest estimate$24.80M$107.21M$1.43B$1.76B
Highest estimate$32.80M$141.82M$1.51B$2.12B
Number of analysts31148
A year ago$594.24M$355.14M$816.72M—
Growth vs a year ago−95.0%−64.1%+78.4%—

Financial Statements

Income statement, balance sheet, and cash flow statements.

About this section

Income statement, balance sheet and cash flow history for Telix Pharmaceuticals Limited. Telix Pharmaceuticals Limited has reported as a listed company since 2017. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.

Peer Comparison

Comparables

List of peer companies in the same industry.

Peers, the industry, and the funds that hold TLX.AX14 companies · 8 funds
Compare TLX.AX with its peers, side by sidePremiumRatios, margins, valuation and leverage of the peers below — one table, one glance.Open Comparable Analysis
Peer companies
TickerTypeCompanySectorIndustry
CU6.AXClarity Pharmaceuticals LtdHealthcareMedical - Specialties—
RAD.AXRadiopharm Theranostics LimitedHealthcareBiotechnology—
More Biotechnology companies
TickerTypeCompanySectorExchangeMkt cap
PHMMFPharma Mar, S.A.HealthcareOTC$1.5B
PHRM.CNPharmaTher Holdings Ltd.HealthcareCNQ$9.1M
PHRRFPharmaTher Holdings Ltd.HealthcareOTC$5.3M
PHVSPharvaris N.V.HealthcareNASDAQ$2.2B
PHYOFIXICO plcHealthcareOTC$6.5M
PKTXProtoKinetix, IncorporatedHealthcareOTC$2.7M
PLRXPliant Therapeutics, Inc.HealthcareNASDAQ$36.9M
PLRZPolyrizon Ltd.HealthcareNASDAQ$10.4M
PLURPluri Inc.HealthcareNASDAQ$10.1M
PLXProtalix BioTherapeutics, Inc.HealthcareAMEX$244.5M
PLYXPolaryx Therapeutics, Inc. Common StockHealthcareNASDAQ$66.3M
PMCBPharmaCyte Biotech, Inc.HealthcareNASDAQ$2.2M
ETFs holding Telix Pharmaceuticals Limited
TickerFundFund assets% of the fund
VXUSVanguard Total International Stock ETF$163.2B in assets0.01%
VEAVanguard FTSE Developed Markets ETF$231.6B in assets0.01%
IEFAiShares Core MSCI EAFE ETF$188.8B in assets0.01%
SCZiShares MSCI EAFE Small-Cap ETF$12.6B in assets0.07%
ISCFiShares International Small-Cap Equity Factor ETF$717M in assets0.07%
IPACiShares Core MSCI Pacific ETF$2.6B in assets0.03%
VPLVanguard FTSE Pacific ETF$9.0B in assets0.02%
DFISDimensional - International Small Cap ETF$5.8B in assets0.02%

Largest holders first, then the funds most concentrated in TLX.AX.

Open Comparable Analysis
Ownership & News

News

Latest headlines and market coverage.

About this section

Latest headlines and company announcements for Telix Pharmaceuticals Limited. Coverage tracks Telix Pharmaceuticals Limited within Biotechnology (Healthcare). Press releases and market coverage, newest first.

Discussion

Comments

Comments and replies from FRC members about this company.

No comments yet

Be the first to ask a question or say what you make of Telix Pharmaceuticals Limited.

TLX.AX AnalysisFair
Past
1
Growth
5
Health
3
Profit
2
Value
1